Embodiments herein include medical devices and methods for using the same to treat cancerous tumors within a bodily tissue. In an embodiment, a medical device is included. The medical device can include an electric field generating circuit configured to generate one or more electric fields and control circuitry in communication with the electric field generating circuit. The control circuitry can be configured to control the generation of one or more electric fields from the electric field generating circuit. The control circuitry can cause the electric field generating circuit to deliver one or more electric fields at one or more frequencies selected from a range of between 10 kHz to 1 MHz to a cancerous tumor located within a bodily tissue. Other embodiments are also included herein.

Embodiments herein relate to medical devices including volume filling leads and methods of use to treat cancerous tumors within a bodily tissue. In an embodiment, a lead for a cancer treatment system is described. The lead can include a lead body having a proximal end and a distal end, where the lead body can define a lumen. The lead can include an expandable lead head connected to the distal end of the lead body, where the lead head can be configured to be expanded between a first non-expanded position and a second expanded position in order to fill an intracorporeal void. The lead can include two or more electrodes disposed on an outer surface of the lead head and two or more electrical conductors configured to provide electrical communication between the two or more electrodes and the proximal end of the lead body. Other embodiments are also included herein.

Embodiments herein relate to medical devices including electric field shaping leads and methods for using the same to treat cancerous tumors within a bodily tissue. In an embodiment, an implantable lead for a cancer treatment system is disclosed. The lead can include a lead body having a proximal end and a distal end, where the lead body can define a lumen. The lead can also include a paddle disposed at the distal end of the lead body, the paddle having a width that is greater than a width of the lead body. The paddle can include one or more electrodes disposed on the paddle and one or more electrical conductors disposed within the lumen of the lead body to provide electrical communication between the one or more electrodes and the proximal end of the lead body. Other embodiments are also included herein.

An adaptive control method for controlling EP pulse parameters during electroporation (EP) of cells or tissue using an EP system includes providing a system for adaptive control to optimize EP pulse parameters including EP pulse parameters, applying voltage and current excitation signals to the cells, obtaining data from the current and voltage measurements, and processing the data to separate the desirable data from the undesirable data, extracting relevant features from the desirable data, applying at least a portion of the relevant features to a trained diagnostic model, estimating EP pulsing parameters based on an outcome of the applied relevant features, where the initialized EP pulsing parameters are based on the trained model and the relevant features, to optimize the EP pulsing parameters, and applying, by the generator, a first EP pulse based on the first pulsing parameters.

Disclosed herein is an implantable electronic device for use with an implantable medical lead. The implantable electronic device includes a housing and a header connector assembly coupled to the housing and adapted to receive the proximal lead end of the implantable medical lead. The header connector assembly includes a connector assembly including a connector, a feedthru extending through the housing, and a conductor coupling the feedthru to the connector. The conductor includes a first conductor segment and a second conductor segment offset from the first conductor segment and each of the first conductor segment and the second conductor segment are resistance welded to the connector.

Embodiments herein relate to medical device systems including electric field shaping elements for use in treating cancerous tumors within a bodily tissue. In an embodiment, a method for treating a cancerous tumor is provided. The method can include implanting one or more electrodes within a patient and measuring the impedance of tissue within the patient along a vector passing through or near a cancerous tumor. The method can also include administering an electric field to the cancerous tumor of the patient based on the measured impedance. Other embodiments are also included herein.

An oral appliance for the treatment of sleep disorders, such as obstructive sleep apnea, in a user is presented. The oral appliance may include a mouthpiece configured to receive a user's dentition. The mouthpiece may include an oxygen sensor, a pressure sensor, an airflow sensor, an actigraphy sensor, a noise detector, and at least one stimulator for providing stimulation to a user's tongue in the event of decreased oxygen saturation levels, increased pressure applied to occlusal surfaces of the user's dentition, decreased actual airflow levels and/or increased noise levels. The mouthpiece may be provided with pharmaceutical compound reservoirs that deliver pharmaceutical compounds to the oral mucosa of the user, which compounds treat symptoms of sleep apnea. The mouthpiece may further include a microprocessor that receives data from the oxygen sensor, pressure sensor, airflow sensor, actigraphy sensor and noise detector, and activates the at least one stimulator and/or pharmaceutical compound reservoirs.

Several embodiments disclosed herein relate to the delivery of therapeutic nucleic acids to an ocular tissue in order to provide a therapeutic effect to reduce symptoms of or otherwise alleviate an ocular disorder. In particular embodiments, plasmid DNA is delivered to the cells of the trabecular meshwork in order to ameliorate increasing intraocular pressure. Devices and systems to accomplish this delivery are also disclosed.

Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.

An electroporation device with a needle array removably attached thereto, the needle array having a body, a shroud movable with respect to the body between a rest position and one or more actuated positions, and an auto-lock assembly. Where the auto-lock assembly is adjustable between a locked configuration, where the shroud is not movable with respect to the body, and an unlocked configuration, where the shroud is movable with respect to the body, and where biasing the shroud from the rest position to the one or more actuated positions and back to the rest position adjusts the auto-lock from the unlocked configuration to the locked configuration.